搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按相关度排序
按时间排序
1 天
Seniors Shielded: New RSV Vaccine Shows 80% Effectiveness
Recent findings from a multi-state study reveal that the RSV vaccine is approximately 80% effective in preventing severe ...
2 天
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging ...
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
4 天
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...
The American Journal of Managed Care
4 天
FDA Approves Abrysvo RSV Vaccine for Adults at Increased Risk
Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.
Medpage Today on MSN
4 天
FDA Expands Approval of RSV Vaccine Abrysvo to Include All At-Risk Adults
The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...
4 天
on MSN
Pfizer Receives Expanded FDA Approval for RSV Vaccine
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...
4 天
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory ...
The Pharma Letter
2 天
New data for GSK’s Arexvy RSV vaccine
US pharma major GSK yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant ...
BioSpace
4 天
Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population
Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.
Zacks.com on MSN
4 天
PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo
The FDA approves Pfizer's RSV vaccine, Abrysvo, for adults aged 18-59 years with increased risk of the disease.
PharmTech
3 天
FDA Approves RSV Vaccine
Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at ...
GlobalData on MSN
4 天
FDA expands Pfizer’s RSV vaccine label to include all high-risk adults
Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults over 18 years of age.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈